Stryker Corp. Stock - Weekly review and sector comparison
19.06.2026 - 18:24:30 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 16:20 UTC. Details in the imprint.
Stryker Corp. (US8636671013) stock has delivered a positive weekly performance in a firm US medical-technology sector. The week closes without major company-specific news, so the focus shifts to how Stryker compares with its orthopedic and medtech peers.
All news and background on Stryker Corp. stock
Key figures, earnings documents and news help frame Stryker’s valuation and sector positioning for equity investors.
How Stryker shares performed
On Thursday, 06/18/2026, Stryker shares closed at $308.62 on the New York Stock Exchange, up 0.26% on the day according to MarketBeat data. After-hours trading showed $307.50, 0.36% below the official close.
On a weekly view, Stryker shares have gained meaningfully from levels around the low $300s at the start of the week. The move reflects a broadly constructive backdrop for large US medical-technology names rather than a specific company catalyst.
Position in the medtech peer group
Stryker operates alongside major peers such as Johnson & Johnson’s MedTech division, Zimmer Biomet and Boston Scientific in the medical-technology and orthopedic-implant space. Investors often compare these companies based on growth, margins and exposure to elective procedures.
Based on recent pricing, Stryker’s market capitalization is in the upper double-digit billion-dollar range, underlining its status as one of the larger pure-play medtech companies globally. The stock is also a member of the Standard & Poor's 500 index, which keeps it on the radar of global index and ETF investors.
What the latest earnings showed
For the first quarter of 2026, Stryker reported earnings per share of $2.60 on revenue of $6.02 billion, according to MarketBeat’s summary of the results. Consensus expectations had been for EPS of $2.98, so the quarter came in below analyst forecasts.
Despite the earnings miss, management guided full-year 2026 EPS to a range of $14.90 to $15.10, broadly in line with the $14.95 consensus cited by MarketBeat. That guidance signals confidence in underlying demand for orthopedic implants, surgical products and related capital equipment.
Analyst expectations and next earnings date
MarketBeat data indicate that Stryker’s next earnings release is estimated for Thursday, 07/30/2026, based on past reporting patterns, although the company has not officially confirmed the date. Investors will watch whether procedure volumes and pricing trends support the 2026 guidance corridor.
The same source aggregates consensus EPS expectations for the full year near the midpoint of the guided range. That suggests analysts see Stryker largely executing on plan, even after the softer first-quarter earnings print.
How the business makes money
Stryker generates most of its revenue from orthopedic implants, trauma and extremities products, and a broad range of surgical equipment and neurotechnology solutions. These include hip and knee replacement systems, trauma fixation devices and capital equipment for operating rooms.
Where the stock trades today
The shares of Stryker Corp. (US8636671013) trade on the New York Stock Exchange at $308.62 as of 06/18/2026, 15:59 Eastern Time.
Key facts on Stryker Corp. stock
- Company: Stryker Corp.
- ISIN: US8636671013
- WKN: 864952
- Ticker: SYK
- Venue: New York Stock Exchange
- Price (as of 06/18/2026, 15:59 Eastern Time): 308.62 USD
- Market cap: around 117,000,000,000 USD (as of 06/18/2026 based on closing price and latest share count)
- Sector / Industry: Health Care / Medical Technology and Orthopedic Devices
- Index membership: Standard & Poor's 500 index
- Next earnings date: estimated 07/30/2026 (not officially scheduled)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
